Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference

Andrew Kennedy*, Lourens Bester, Riad Salem, Ricky A. Sharma, Rowan W. Parks, Philippe Ruszniewski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

ObjectivesLiver metastasis from a neuroendocrine tumour (NET) represents a significant clinical entity. A multidisciplinary group of experts was convened to develop state-of-the-art recommendations for its management.

MethodsPeer-reviewed published reports on intra-arterial therapies for NET hepatic metastases were reviewed and the findings presented to a jury of peers. The therapies reviewed included transarterial embolization (TAE), transarterial chemoembolization (TACE) and radioembolization (RE). Two systems were used to evaluate the level of evidence in each publication: (i) the US National Cancer Institute (NCI) system, and (ii) the GRADE system.

ResultsEighteen publications were reviewed. These comprised 11 reports on TAE or TACE and seven on RE. Four questions posed to the panel were answered and recommendations offered.

ConclusionsStudies of moderate quality support the use of TAE, TACE and RE in hepatic metastases of NETs. The quality and strength of the reports available do not allow any modality to be determined as superior in terms of imaging response, symptomatic response or impact on survival. Radioembolization may have advantages over TAE and TACE because it causes fewer side-effects and requires fewer treatments. Based on current European Neuroendocrine Tumor Society (ENETS) Consensus Guidelines, RE can be substituted for TAE or TACE in patients with either liver-only disease or those with limited extrahepatic metastases.

Original languageEnglish
Pages (from-to)29-37
Number of pages9
JournalHPB
Volume17
Issue number1
DOIs
Publication statusPublished - Jan 2015

Keywords

  • SELECTIVE INTERNAL RADIOTHERAPY
  • QUALITY-OF-LIFE
  • ENDOCRINE TUMORS
  • ARTERIAL CHEMOEMBOLIZATION
  • RADIOFREQUENCY ABLATION
  • Y-90 RADIOEMBOLIZATION
  • BLAND EMBOLIZATION
  • 1ST-LINE TREATMENT
  • ELUTING BEADS
  • MICROSPHERES

Fingerprint

Dive into the research topics of 'Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference'. Together they form a unique fingerprint.

Cite this